(August 21, 2023, 12:22 PM EDT) -- WILMINGTON, Del — An abbreviated new drug application (ANDA) to manufacture and market a generic version of the anti-seizure medication “Briviact” would infringe a single claim of a patent directed to the drug’s active ingredient, an analogue of the compound levetiracetam, a federal judge in Delaware has concluded after a bench trial....